IRLAB presents integrated analysis of mesdopetam data at international conference – confirms robust efficacy results in the Phase II studies

Gothenburg, Sweden, June 16, 2026 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson’s disease, today announces that an integrated analysis of clinical data for mesdopetam, IRLAB’s most advanced drug candidate in development to treat levodopa-induced dyskinesia, will be presented at StanCon 2026 in Uppsala in August. The analysis confirms mesdopetam’s anti-dyskinetic effect across a broad range of statistical models – a conclusion that strengthens the project’s attractiveness in ongoing partnering discussions.

The subscription period in IRLAB’s rights issue commences today

IRLAB publishes information document in connection with the rights issue and announces that additional subscription undertakings have been received